


1624#9
5/22/02
89W

CERTIFICATE OF MAILING
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, U.S. Patent and Trademark Office, Box Patents, P.O. box 2327, Arlington, VA 22202-0327, on the date appearing below.
By Linda M. Dunbar ELI LILLY AND COMPANY Date May 15, 2002



PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

RECEIVED
MAY 21 2002

Applicants : Krushinski, et al.)
Serial No. : 09/890,741 ✓)
Filed : December 4, 2001 ✓) Group Art Unit: 1624
For : 5-HT1F AGONISTS ✓) Examiner: Sudhaker Patel
Docket No. : X-11704)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Arlington, VA 22202
Sir:

As a means of further complying with the duty of disclosure, Applicants submit the attached second "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) for consideration by the Examiner.

This second Form PTO-1449 differs from the first, submitted January 16, 2002, by the addition of references AA (U.S. Patent 5,942,536), AB (U.S. Patent 5,708,008), and AC (U.S. Patent 5,962,474).

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b)(3), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

R. Craig Tucker
Attorney for Applicants
Registration No. 45,165
Phone: 317-433-9829

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

May 15, 2002